- Home
- MHLD vs CKPT Comparison
MHLD vs CKPT Comparison
Compare MHLD & CKPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MHLD
- CKPT
- Stock Information
- Founded
- MHLD 2007
- CKPT 2014
- Country
- MHLD Bermuda
- CKPT United States
- Employees
- MHLD N/A
- CKPT N/A
- Industry
- MHLD Property-Casualty Insurers
- CKPT Biotechnology: Pharmaceutical Preparations
- Sector
- MHLD Finance
- CKPT Health Care
- Exchange
- MHLD Nasdaq
- CKPT Nasdaq
- Market Cap
- MHLD 137.1M
- CKPT 151.9M
- IPO Year
- MHLD 2008
- CKPT 2017
- Fundamental
- Price
- MHLD $1.21
- CKPT $3.18
- Analyst Decision
- MHLD
- CKPT Strong Buy
- Analyst Count
- MHLD 0
- CKPT 2
- Target Price
- MHLD N/A
- CKPT $13.50
- AVG Volume (30 Days)
- MHLD 249.9K
- CKPT 1.3M
- Earning Date
- MHLD 03-11-2025
- CKPT 11-12-2024
- Dividend Yield
- MHLD N/A
- CKPT N/A
- EPS Growth
- MHLD N/A
- CKPT N/A
- EPS
- MHLD N/A
- CKPT N/A
- Revenue
- MHLD $89,074,000.00
- CKPT $47,000.00
- Revenue This Year
- MHLD N/A
- CKPT N/A
- Revenue Next Year
- MHLD N/A
- CKPT $172,016.02
- P/E Ratio
- MHLD N/A
- CKPT N/A
- Revenue Growth
- MHLD 20.80
- CKPT N/A
- 52 Week Low
- MHLD $1.16
- CKPT $1.38
- 52 Week High
- MHLD $2.27
- CKPT $4.50
- Technical
- Relative Strength Index (RSI)
- MHLD 43.16
- CKPT 42.32
- Support Level
- MHLD $1.16
- CKPT $3.07
- Resistance Level
- MHLD $1.33
- CKPT $3.42
- Average True Range (ATR)
- MHLD 0.13
- CKPT 0.21
- MACD
- MHLD 0.00
- CKPT -0.02
- Stochastic Oscillator
- MHLD 9.09
- CKPT 15.71
About MHLD Maiden Holdings Ltd.
Maiden Holdings Ltd provides reinsurance products and services to regional and specialty property and casualty insurers. The company operates in two segments: AmTrust Reinsurance and Diversified Reinsurance. The AmTrust Reinsurance segment provides products that cover workers' compensation, commercial package, commercial auto, and extended warranty. The Diversified Reinsurance segment provides small and midsize regional and specialty insurers with reinsurance capital products. Its revenues also include fee income earned from both its GLS business and IIS business as well as income generated from its investment portfolio.
About CKPT Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.